
Applied Therapeutics APLT
Quartalsbericht 2025-Q3
hinzugefügt 13.11.2025
Applied Therapeutics Gesamtes Eigenkapital 2011-2026 | APLT
Gesamtes Eigenkapital Jährlich Applied Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17.1 M | 4.06 M | 62.5 M | 81.9 M | 32.6 M | -19.6 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 81.9 M | -19.6 M | 24.1 M |
Gesamtes Eigenkapital Vierteljährlich Applied Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -561 K | 17.4 M | 57 M | 5.89 M | 72.4 M | -17.1 M | -11 M | -4.33 M | -4.07 M | 4.06 M | 9.63 M | 25.8 M | 42 M | 62.5 M | 86.7 M | 112 M | 135 M | 81.9 M | 81.9 M | 81.9 M | 81.9 M | 32.6 M | 32.6 M | 32.6 M | 32.6 M | -19.6 M | -19.6 M | -19.6 M | -19.6 M | -3.96 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 135 M | -19.6 M | 32.3 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
884 M | $ 219.68 | 1.92 % | $ 5 B | ||
|
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Seres Therapeutics
MCRB
|
-44.9 M | $ 8.28 | - | $ 1.06 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 19.45 | 1.14 % | $ 909 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | ||
|
Mesoblast Limited
MESO
|
497 M | $ 15.44 | 7.82 % | $ 10 B | ||
|
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | ||
|
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
13.5 M | $ 0.67 | -5.25 % | $ 7.67 M | ||
|
Mirum Pharmaceuticals
MIRM
|
315 M | $ 90.39 | 2.86 % | $ 4.54 B | ||
|
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.34 | 1.52 % | $ 342 M | ||
|
MediciNova
MNOV
|
41.6 M | $ 1.45 | - | $ 71.1 M | ||
|
CytomX Therapeutics
CTMX
|
99 M | $ 4.37 | 2.95 % | $ 603 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
-2.17 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
19 M | $ 2.69 | 1.37 % | $ 16.9 M | ||
|
Dynavax Technologies Corporation
DVAX
|
597 M | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
-21.3 M | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
Merck & Co.
MRK
|
52.6 B | $ 117.56 | 1.02 % | $ 294 B | ||
|
Marker Therapeutics
MRKR
|
16.8 M | $ 1.37 | 8.73 % | $ 21 M | ||
|
Moderna
MRNA
|
8.65 B | $ 53.09 | 3.41 % | $ 20.7 B | ||
|
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
76.6 M | $ 4.47 | 3.71 % | $ 856 M | ||
|
Homology Medicines
FIXX
|
42 M | - | 0.77 % | $ 53.4 M |